← SynDRA
SPEBRUTINIB
SynDRA canonical compound SYN0038051 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | BTK |
|---|
| Mechanism of action | BTK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- BTK INHIBITOR
- Tyrosine-protein kinase BTK inhibitor
- YES1 INHIBITOR
- Bruton's tyrosine kinase (BTK) inhibitor
- BTK MODULATOR
Cross-references
Synonyms
- ESPEBRUTINIB
- BTK INHIBITOR CC-292
- AVL-292
- AVL292
- CC-292
- LMK-435
- SPEBRUTINIB (CC-292)
- Spebrutinib besylate
- AVL 292
- CC 292
- Btk inhibitor CC-292
- DRU6NG543J
- Espebrutinib
- spebrutinibum
- RefChem:888489
- Bruton's Tyrosine Kinase Inhibitor CC-292
- C22H22FN5O3
- Spebrutinib [USAN:INN]
- UNII-DRU6NG543J
- MFCD25976876
- Spebrutinib (AVL-292)
- CC-292 (AVL-292)
- SPEBRUTINIB [INN]
- Spebrutinib (USAN/INN)
- SPEBRUTINIB [USAN]
- SPEBRUTINIB [WHO-DD]
- SCHEMBL626216
- GTPL7837
- orb1305275
- SCHEMBL29359972
- EX-A255
- KXBDTLQSDKGAEB-UHFFFAOYSA-N
- GLXC-90261
- HMS3653E15
- HMS3674E05
- AVL-292?
- BDBM50161162
- NSC780020
- s7173
Look up SPEBRUTINIB in the interactive SynDRA portal →